Table 5.
Characteristics and outcomes of LN cases with two APOL1 risk alleles.
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Age at recruitment | 28 | 51 | 29 | 32 |
| Sex | Female | Female | Female | Female |
| Ancestry | Black | Mixed | Black | Mixed |
| SLICC criteria | 8 | 5 | 4 | 8 |
| LN duration, months | 120 | 47 | 70 | 42 |
| Kidney biopsy | LN class IV-S | LN class IV-G/V | LN class IV-S/V | LN class V |
| Crescents, % | 10 | 0 | 0 | 0 |
| Global sclerosis, % | 36.8 | 25 | 25 | 0 |
| TA/IF, % | 50–75 | 50–75 | <25 | <25 |
| AI/CI | 3/6 | NA | 6/4 | 0/2 |
| Treatment | CF, MMF, steroids | CF, MMF, steroids | CF, MMF, CsA, steroids | CF, MMF, steroids |
| eGFR, mL/min (CKD-EPI) last follow-up | 28 | 18 | 140 | 113 |
| Outcome | CKD stage 4 | CKD stage 4 | Partial response | Complete response |
| APOL1 genotype | G1G1 | G1G1 | G1G1 | G1G1 |
Abbreviations: SLICC, Systemic Lupus International Collaborating Clinics Classification Criteria; LN, lupus nephritis; TA, tubular atrophy; IF, interstitial fibrosis; AI, activity index; CI, chronicity index; NA, not available; CF, cyclophosphamide; MMF, mycophenolate mofetil; CsA, cyclosporine; CKD, chronic kidney disease.